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Primary Aldosteronism: A 
Glimpse into the Most Common 
Endocrine Cause of Arterial 
Hypertension
Gian Paolo Rossi and Teresa M. Seccia
Abstract
Compelling evidences showed that primary aldosteronism (PA) is a quite common 
disease. In spite of this, hypertensive patients are seldom screened for PA and, there-
fore, many patients are mislabelled as (low-renin) essential hypertension thereby 
remaining exposed to the nefarious consequences of long-term hyperaldosteronism. 
In this chapter we reviewed the clinical aspects of PA and the evidences supporting 
the need of implementing strategies aimed at diagnosing early PA patients. After 
reporting the prevalence rates of PA in different cohorts of hypertensive patients, 
we examined the reasons why PA is rarely searched for. The cardiovascular and renal 
damage associated with PA were also discussed, with particular emphasis to endo-
thelial dysfunction, vascular remodeling, left ventricular changes, fibrosis, diastolic 
dysfunction, atrial fibrillation and chronic kidney disease. Studies supporting the 
concept that PA-associated organ damage can be prevented and even regressed 
with a timely diagnosis were also reviewed. A flowchart illustrating the proposal of 
a simplified diagnostic algorithm for screening and subtyping of PA, which allows 
circumventing the complexity of a diagnostic workup centred on confirmatory tests, 
is also proposed. Finally, the principles of treatment for PA are discussed.
Keywords: endocrine hypertension, primary aldosteronism, subtyping, diagnosis, 
adrenal vein sampling, outcome
1. Epidemiology
Primary aldosteronism (PA) is regarded by most practicing physicians as a 
‘needle in the haystack’ [1], notwithstanding compelling evidences supporting the 
opposite view that is quite common. At the dawn of this millennium, based on small 
single-centre retrospective studies, the prevalence rate of PA was estimated to range 
from 1.4–32% (median 8.8%), i.e. so widely that no firm conclusions could be drawn 
on how common PA was, likely because of differences in the selection of the patient’s 
cohorts and heterogeneous diagnostic criteria used in the various studies [2].
In 2006, the PA Prevalence in Hypertensives (PAPY) study, a prospective survey 
of consecutive newly diagnosed hypertensive patients referred to specialized 
hypertension centres, exploited for the first time use of a predefined protocol and 
standardized diagnostic criteria to diagnose PA [3]. This seminal study provided 
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solid evidences that among referred hypertensive patients the prevalence of PA was 
high, i.e. 11.2% [3]. Moreover, by calling attention to the fact that the only subtype 
of PA that could be diagnosed with certainty is aldosterone-producing adenoma 
(APA), this study introduced the ‘four-corners criteria’ to diagnose PA due to APA, 
a concept thereafter adopted in the PASO criteria [4] and recently revised to take 
into consideration the availability, thanks to Gomez-Sanchez’s laboratory, of a 
monoclonal antibody for human aldosterone synthase (CYP11B2) that allowed the 
immunohistochemical demonstration of aldosterone biosynthesis in adrenocortical 
nodule(s) of excised adrenals [5, 6].
It should be acknowledged, though, that estimates of the prevalence of PA are 
meaningless figures without specification of the cohort of hypertensive patients 
that are being considered. For example, in a general population survey in Japan, 
Ito et al. reported a prevalence of PA of 6.8% in prehypertensive subjects and 3.3% 
and 3.2%, respectively, in stage I and II hypertensive patients [7]. In the Bussolengo 
study, which involved hypertensive patients seen in general practice in Verona 
province in Italy, 34% were found to have an elevated aldosterone-to-renin ratio 
(ARR) suggesting PA [8]. Although the actual rate of those with confirmed PA 
remained uncertain, because no further tests could be undertaken, those findings 
suggested a high prevalence of PA among such unselected hypertensive patients. In 
line with this suggestion, in a similar study involving general practitioners in Torino 
(Italy), 5.9% of the patients were found to have PA [9]. Altogether these results led 
to the proposal that the screening for PA should be wider [10] than a screening only 
in selected categories of patients recommended by current guidelines [11].
Undoubtedly, screening should be exploited in patients with drug-resistant 
hypertension, which represent the cohort at the highest cardiovascular risk, not 
only because of the uncontrolled blood pressure (BP) values, but also because of 
the common concurrence of hypertension-mediated organ damage (HMOD) [9, 
11–14]. In a single-centre study carefully carried out in Greece by Douma et al. in 
drug-resistant hypertension patients, who were studied after wash-out from inter-
fering drugs, 20.6% were found to have a high ARR [15]. The rate fell to about 11% 
when the authors used the BP-lowering response to spironolactone to confirm their 
diagnosis. They considered this rate to be not as high as they expected [15]. However, 
yet unpublished data from the AVIS-2 study, the largest registry of patients submit-
ted to adrenal vein sampling (AVS) for the subtyping of PA worldwide, indicated 
Figure 1. 
Prevalence of a disease affects positive and negative predictive values. Furthermore, the diagnostic gain of a test 
is maximized when the prevalence of the disease is between 10 and 30%. Since primary aldosteronism (PA) 
was found to involve 11.2% in the hypertensive patients referred to the specialized centres for hypertension, 
and to be even more prevalent in the ‘resistant’ hypertensives, implementation of the screening strategies for PA 
furnishes an unambiguous gain in these categories, besides being of crucial relevance for identifying the patients 
who can benefit of the targeted treatment.
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that between 20.1 and 49.5% of PA patients, depending on the criteria used to define 
this condition, have drug-resistant hypertension. Hence, resistant hypertension is a 
common presentation of PA. On the whole, these results showed that, at least among 
referred hypertensives who are carefully investigated, more than 11% have PA, with 
a rate that increases together with the stage of hypertension.
Hence, besides supporting the original contention of Conn [16], these findings 
showed that PA is by no means an exceptionally rare cause of human hypertension. 
Therefore, they have implications of paramount importance for the implementa-
tion of screening strategies in the hypertensive patients as the diagnostic gain of a 
diagnostic test is maximized when the prevalence of the disease that is sought for is 
between 10 and 30% (Figure 1).
2. Why PA is under-detected?
In spite of the fact that compelling evidences support the notion that PA is a 
common curable form of secondary hypertension, this condition remains mark-
edly underdiagnosed for a number of reasons. The first is the misbelief that it 
is rare and therefore it is not worth of a search. The second entails the fact that 
hypokalaemia, which for decades has been considered the hallmark of PA, occurs 
only in less than half of the hypertensive patients, with APA and in less than 20% 
of those with bilateral adrenal hyperplasia (BAH, also known as idiopathic hyperal-
dosteronism, IHA) [3]. The third reason is a general phenomenon in medicine: the 
time lag occurring between publication of scientific data, their incorporation into 
practice guidelines and implementation of guidelines’ recommendations in clini-
cal practice. A survey of general practitioners in Italy and Germany documented 
that this is true also for PA: only 1 and 2%, respectively, in these countries were 
ever screened for PA by their general practitioners [17]. The fourth major reasons 
for the underscreening and consequent underdiagnosis of PA relate, in our view, 
to the fact that the diagnostic workup of patients for PA is perceived by practicing 
physicians as too complex to undertake and interpret. The recommended measure 
to prepare the hypertensive patients pharmacologically with a complete wash-out 
from drugs, which is totally unjustified, or better a switch to non-interfering drugs 
before undertaking the screening tests, is perceived as risky, even though evidence 
supporting the safety of a transient withdrawal of antihypertensive treatment exists 
[18, 19]. Uses of different assays to measure renin and aldosterone and of different 
units of measure are further factors undoubtedly confusing the interpretation of 
the screening test, which led us to develop an app that has been made freely avail-
able to address these difficulties [20] (https://siia.it/attivita-ricerca/iniziative/
una-app-per-calcolare-l-arr/).
As a result of the under diagnosis, far too many PA patients are misdiagnosed 
as (low-renin) essential hypertension and remain exposed to the nefarious conse-
quences of long-term exposure to hyperaldosteronism [21, 22], which are described 
in the next section.
3. Cardiovascular and renal damage associated with PA
Patients with PA have higher cardiovascular morbidity and mortality than age-, 
sex- and BP-matched patients with essential hypertension [9, 13, 14, 23, 24]. This 
is because aldosterone excess, in the presence of a normal-to-high salt intake, has 
deleterious effects on the cardiovascular system that aggravate those of high BP, as 
convincingly demonstrated in both experimental and clinical studies [25–28].
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In 1991, Karl Weber’s and Richardo Rocha’s laboratories provided unambiguous 
evidences that uni-nephrectomized salt-fed rats infused with aldosterone devel-
oped prominent inflammation and fibrosis in the heart and kidneys. Moreover, they 
showed that these changes could be prevented by pretreatment with mineralocor-
ticoid receptor antagonists, as spironolactone, even at sub-antihypertensive doses, 
suggesting that aldosterone can cause fibrosis independently of its pressor effects 
[25, 29]. Moreover, in animal models, aldosterone infusion was shown to cause 
endothelial dysfunction via reactive oxygen species (ROS) generation; increased 
expression of NADPH oxidase subunits p22phox, gp91phox and p47phox; forma-
tion of peroxynitrite; oxidation of the NOS cofactor BH4 (5,6,7,8-tetrahydrobiop-
terin); and decreased G6PD (glucose-6-phosphate dehydrogenase) [30, 31].
In 1996, at a time when PA was still regarded as a ‘benign’ form of arterial 
hypertension, we reported that PA patients developed more left ventricular (LV) 
hypertrophy (LVH) than age-, sex- and BP-matched essential hypertensive patients, 
[32] and that this was particularly evident in those who showed more florid PA phe-
notypes due to an APA [13]. These findings were thereafter extended to show that 
they are more prone to develop fibrosis, atrial fibrillation [33], vascular remodeling 
[34], endothelial dysfunction [35, 36], increased carotid intima-media thickness 
and femoral pulse wave velocity, more frequently than those with essential hyper-
tension [13, 14, 32, 37].
Moreover, the occurrence of LVH, LV fibrosis, impaired diastolic function, atrial 
dilatation and electric remodeling in PA (rev in [38]) explains why these patients 
were found to have a 12-fold higher risk of developing atrial fibrillation, the most 
common arrhythmia worldwide, than essential hypertensive patients in a French 
retrospective study [39]. Accordingly, adrenalectomy was found to lower the risk 
of atrial fibrillation in PA patients in the long-term longitudinal phase of the PAPY 
study [33]. Collectively these evidences support the concept that aldosterone favors 
atrial fibrillation [38] and that PA patients are more susceptible to heart failure 
with onset of atrial fibrillation [13, 40] because of a ‘stiffer’ LV causing LV diastolic 
dysfunction and fibrosis, which lead to a greater dependency of the LV on the atrial 
kick for its filling.
PA patients also develop more renal damage with development of proteinuria 
and/or chronic kidney disease. In 1988, Danforth et al. first reported moderate to 
severe renal parenchymal damage in renal biopsies of patients with PA [41], a find-
ing confirmed two decades later by Nishimura et al. [42] and, in 2006, by the PAPY 
study, which reported higher albumin excretion rate in PA patients than in matched 
essential hypertensives [14].
The important notion to be considered in this context is that most of the 
hypertension-mediated organ damage associated with PA can be prevented and 
even regressed, at least partially, with a timely diagnosis. For example, in a long-
term observational study, long-term regression of LVH and a decrease incidence of 
AF were documented [43]. Moreover, in the longitudinal phase of the PAPY study, 
we found that incident AF was significantly decreased by adrenalectomy, but not 
by long-term medical treatment [33]. In line with such findings Hundemer et al. 
[40] reported that PA patients with persistently suppressed renin despite treat-
ment with mineralocorticoid receptor antagonists had a higher risk of AF than 
essential hypertensives, or patients on treatment with mineralocorticoid receptor 
antagonists and increased renin (suggesting optimal mineralocorticoid receptor 
blockade), or adrenalectomized PA patients.
A long-term follow-up study by Sechi et al. [44] showed that in PA renal 
damage could be reversed by target treatment, a finding thereafter supported by 
Hundemer et al. [45], who showed that glomerular filtration rate declined more in 
PA patients treated with mineralocorticoid receptor antagonists than in essential 
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hypertension patients and in PA cured with adrenalectomy. Rapid regression of 
microalbuminuria in PA suggests that urinary albumin excretion is, at least in part, 
due to functional rather than structural renal changes, i.e. glomerular hyperfiltra-
tion and decreased intrarenal vascular resistance. Elegant studies by Hall et al. in 
dogs exposed to hyperaldosteronism while renal perfusion pressure was maintained 
constant support this contention [46].
Thus, early screening and identification of PA patients who need surgery is 
needed to prevent/regress morbid events caused by hyperaldosteronism.
4. Screening of PA
The diagnosis of PA requires demonstration of an excessive aldosterone secre-
tion autonomous of the renin-angiotensin system [11]. This implies concomitant 
measurement of plasma aldosterone and renin levels, Na+ and K+ in serum and 
24-hour urine, followed by calculation of the aldosterone-to-renin ratio (ARR) [11]. 
Nowadays, the measurement of direct renin concentration has replaced plasma 
renin activity (PRA) in many laboratories because it is simpler, quicker and more 
accurate in the low range typically seen in PA [47]. However, the optimal cutoff 
value of the ARR is still a matter of debate and for optimal use they should be 
determined at each centre. Based on a prospective validation using a solid diagnosis 
of PA due to APA diagnosed as previously mentioned, we use 2.06 ng/dl/mUI/L 
(=20.6 ng/mUI) if renin is estimated by DRC or 26 ng/dl/ng/ml/h if renin was 
measured as PRA [47]. The aforementioned ARR-App can render the interpretation 
of results straightforward for practicing physicians and avoids the errors that might 
occur with unit conversion and calculations [20].
5. Confirmatory tests
Confirmatory tests are still used in most centres, even though there is clear-cut 
evidence that at the prevalence rate of PA seen in referral centres, i.e. between 11 
and 30%, their negative predictive value largely exceeds their positive predictive 
value [48], and, therefore, these tests function as ‘exclusion tests’. These tests stand 
on the unproven hypothesis that aldosterone secretion is unresponsive to maneuvers 
that perturbate renin. By such premise, they will identify only the subset of PA 
cases that are unresponsive to salt or volume suppression of aldosterone secretion, 
notably a minority of the cases of PA [6, 49].
Therefore, as discussed in depth elsewhere, this is a highly controversial issue 
[49]. Most studies supporting the use of these tests did not follow the STARD recom-
mendations [50]: they attempted to validate the confirmatory tests not against a gold 
reference standard, as the diagnosis of APA, but against another confirmatory test, 
also based on the presumed autonomy of aldosterone secretion from the renin-
angiotensin system [49]. Therefore, they were affected by a tautology bias. The only 
demonstration of CYP11B2-positive nodules at pathology, besides biochemical cure 
of PA after adrenalectomy, provides, in our view, a conclusive diagnosis of PA, which 
can be an APA or unilateral multinodular adrenocortical hyperplasia [5]. Given the 
availability of monoclonal antibodies for human CYP11B2, we recently amended the 
‘four corners’ with the addition of immunohistochemical detection of CYP11B2 in 
the resected adrenal for the diagnosis of APA [3]. Likely considering the complexity 
and the intrinsic inaccuracy of the confirmatory tests, the last Endocrine Society 
guidelines for the first time foresaw the possibility of skipping these tests in patients 
with a florid PA phenotype and to proceed directly to subtyping (see later) [11].
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In a recent large-size study comprising an exploratory and validation cohort, we 
investigated the accuracy of one such ‘confirmatory’ tests, the captopril challenge. 
This study provided unambiguous evidence that when a solid diagnosis of APA 
was used as reference index, the quantitative information conveyed by the ARR 
was accurate enough to avoid use of any confirmatory tests and to skip confirma-
tory tests [51]. In fact, neither the fall of plasma aldosterone concentration after 
captopril administration nor the fall of the ARR value furnished any diagnostic 
gain over baseline ARR values in these two very large cohorts of patients [51]. These 
results call for a simplification of the diagnostic algorithm as depicted in Figure 2. 
This strategy decreases the complexity, costs and time of the diagnostic workup for 
PA and therefore could extend the screening to most hypertensive patients, even in 
municipalities with low levels of access to specialized medical care.
6. Subtyping of PA
The most common forms of PA are unilateral causes of PA, mostly APA and 
rarely unilateral multinodular hyperplasia, and bilateral forms (BAH or IHA).  
Figure 2. 
The flow-chart describes a simplified diagnostic algorithm for the work-up of primary aldosteronism (PA). The 
work up is schematically divided into screening, which is based on measurement of plasma aldosterone and renin 
and levels and calculation of the aldosterone-to-renin ratio (ARR), and subtyping that requires adrenal vein 
sampling (AVS). In the screening, given the important information conveyed by the quantitative value of the 
ARR, this test should not be regarded as positive or negative. Instead its actual value should be used to stratify the 
patients for probability of PA. The ARR value must be assessed in the context of 24-hr Na+ urinary excretion and 
serum K+. See text for explanation. Given the unreliable results of the so called “confirmatory tests”, the authors 
do not recommend their use. A clear-cut advantage of this algorithm is its simplicity with ensuing cutting costs 
and, moreover, its being feasible in most centres. AVS is key for subtyping of primary aldosteronism (PA), which 
is indicated only in patients wishing to accomplish long-term cure. Adrenal imaging by CT should be performed 
preliminarily to AVS for two main reasons: to exclude malignant neoplasms (adrenocortical carcinoma, ACC) 
and to assess the anatomy of adrenal veins which can guide interventionists in performing AVS.
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As unilateral PA is best treated with unilateral laparoscopic adrenalectomy, while 
bilateral forms require lifelong mineralocorticoid receptor antagonists, the distinc-
tion between APA and IHA is crucial for choosing the appropriate treatment [11, 52].
There are at last 10 key reasons why AVS should be used to reliably discriminate 
between unilateral and bilateral PA, as reviewed in depth elsewhere [53]. AVS, 
albeit minimally invasive and safe [54], is technically difficult and expensive 
and potentially affected by several factors [55, 56]. For these reasons it should 
be performed only in properly selected patients and in centres with a skilled 
multidisciplinary team that has extensive expertise [11]. As a preliminary test for 
adrenalectomy, it should be reserved for patients seeking long-term cure of PA with 
surgery, who are reasonable candidates for general anesthesia and adrenalectomy. 
Importantly, AVS should be performed after correction of hypokalaemia, if pres-
ent, and adjustment of antihypertensive medications to allow correct interpretation 
of the AVS results [11]. Patients with genetically confirmed familial forms of PA 
[57] usually have bilateral forms of PA and therefore should not be submitted to this 
test unless they have a CT detectable node.
7. Treatment of PA
The Endocrine Society guidelines [11] state that a lateralized aldosterone 
secretion should be demonstrated before undertaking surgery in patients who are 
candidates for general anesthesia and wish to achieve long-term cure. Laparoscopic 
adrenalectomy is currently the best treatment that it can be performed during a 
short hospital stay at a very low operative risk [58].
Overall, surgery cured PA in 33–72% of patients and resulted in marked 
improvements in 40–50% of patients [54]. This wide variation of results is 
explained by the fact that at some centres adrenalectomy is performed on the basis 
of imaging alone that can be misleading in a substantial proportion of patients [54]. 
When performed after demonstration of lateralized aldosterone, excess adrenal-
ectomy cured or determined a marked improvement of hypertension in ~82% of 
the patients, while practically all were biochemically cured from the hyperaldo-
steronism [54]. Even when antihypertensive treatment cannot be withdrawn after 
adrenalectomy, the number and/or the doses of antihypertensive drugs could be 
markedly decreased, and/or resistant hypertension was resolved at long term [54]. 
Adrenalectomy can also lead to a considerable improvement in several indexes of 
quality of life.
The outcome for blood pressure was found to be predicted by the duration of 
hypertension and vascular remodeling, both of which are associated with delayed 
diagnosis (28). Overall available evidence supports the concept that the sooner 
the diagnosis is made and adrenalectomy performed, the better the outcome [54]. 
Failure to achieve cure of PA can be the result of concurrent essential hypertension 
or an inaccurate diagnosis (AVS not performed or results incorrectly interpreted). 
In fact, both the PASO study [4] and the larger AVIS-2 study (manuscript submit-
ted) showed a huge variability in AVS success even at major referral centres. Due 
to the high prevalence of both PA and primary (essential) hypertension, up to one 
third of patients with PA would be expected to have concurrent primary hyperten-
sion. Adrenalectomy can cure only PA, but not hypertension, in these patients.
For patients who are not candidates for surgery or do not show lateralized aldo-
sterone excess, a treatment based on mineralocorticoid receptor antagonists, such 
as spironolactone, canrenone, potassium canrenoate and eplerenone (which is more 
selective but also more expensive, weaker and shorter acting than the other antago-
nists and is not generally available), is a reasonable alternative to adrenalectomy. 
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Spironolactone was found to regress LVH even at doses (37 mg daily) that did not 
completely normalize BP in both PA and low-renin hypertension, supporting a role 
of aldosterone in LVH development [59]. The occurrence of gynaecomastia and 
impotence, the more annoying side effects of the mineralocorticoid receptor antago-
nists, is dose-dependent, which suggests the use of reduced doses in combination, if 
necessary, with other agents, such as long-acting calcium channel blockers, angio-
tensin-converting enzyme inhibitors or angiotensin receptor blockers. Amiloride 
and triamterene have been also proposed in addition to the first-line treatment with 
mineralocorticoid receptor antagonists if BP control is not optimal [60], but these 
drugs are not available as single agent in some counties, and, moreover, the com-
bined therapy needs monitoring of serum potassium and creatinine. Angiotensin-
converting enzyme inhibitors and angiotensin receptor blockers can be particularly 
useful, as they effectively control the counter-regulatory stimulation of the renin-
angiotensin system triggered by the diuretic action of the mineralocorticoid receptor 
antagonists. Aldosterone synthase inhibitors are also being developed and tested in 
phase III trials as an effective strategy to control hyperaldosteronism [61, 62].
8. Future developments
Mutations in the selectivity filter of potassium channels of the KCNJ5 type and 
other genes involved in the regulation of cytosolic calcium in adrenocortical cells 
[57, 63] play an important role in upregulating aldosterone secretion. Few germline 
mutations associated with bilateral adrenal hyperplasia and severe PA have been 
identified, thus allowing identification of further forms of familial hyperaldo-
steronism (6). These discoveries have triggered enormous investigative efforts, 
whose results, which are difficult to anticipate at this time, might lead to change 
our understanding and our diagnostic and therapeutic approach to PA. For the time 
being, following a few simple rules and a streamlined approach (Figure 2), physi-
cians can successfully and cost-effectively identify and treat many patients with the 
so-called ‘essential’ hypertension whose high blood pressure is instead caused by 
hyperaldosteronism. In these patients the clue to PA is a low plasma renin, which 
responds little nothing to stimulatory maneuvers. Identification of PA is particu-
larly beneficial when hypertension is severe and/or resistant to treatment, because 
specific treatment can bring blood pressure under control despite withdrawal or a 
prominent reduction in the number and dosage of antihypertensive medications.
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